Literature DB >> 23262246

The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner.

Yong Yi1, Hong-Wei He, Jia-Xing Wang, Xiao-Yan Cai, Yi-Wei Li, Jian Zhou, Yun-Feng Cheng, Jian-Jun Jin, Jia Fan, Shuang-Jian Qiu.   

Abstract

BACKGROUND & AIMS: The immunosuppressive network within the tumor microenvironment is one of the major obstacles to the success of cancer immunotherapy. γδ T cells are attractive effectors for cancer immunotherapy. Nevertheless, the promising anti-tumor effect in vitro is partially if not totally mitigated in vivo. Thus, understanding the immune status of tumor-infiltrating γδ T cells is essential for orchestrating effective immunotherapy strategies. In this study, we have investigated the immunophenotype and function of γδ T cells in hepatocellular carcinoma (HCC) patients.
METHODS: The phenotype of γδ T cells in peripheral blood, and peritumoral and tumoral tissues of HCC patients (n=61) was characterized by flow cytometry. Functional analysis of the HCC-infiltrating γδ T cells was conducted directly after γδ T cell isolation.
RESULTS: The infiltration of γδ T cells in tumoral tissues was significantly reduced compared to paired peritumoral tissues. Impairment in degranulation of the granule pathway and downregulation of IFN-γ secretion were also demonstrated in HCC-infiltrating γδ T cells, which was in agreement with the results of gene microarray analysis, and further strengthened by the compromised specific cytotoxicity and IFN-γ secretion in vitro. Moreover, isolated HCC-infiltrating CD4(+)CD25(+) regulatory T cells (Treg cells) directly suppressed the cytotoxic function and IFN-γ secretion of γδ T cells in a TGFβ- and IL-10-dependent manner.
CONCLUSIONS: The effector function of γδ T cells was substantially impaired in HCC, which is partially mediated by Treg cells. We propose a new mechanism by which immune privilege develops within the tumor milieu.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23262246     DOI: 10.1016/j.jhep.2012.12.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  46 in total

Review 1.  Virus-induced hepatocellular carcinoma with special emphasis on HBV.

Authors:  Ming Wang; Dong Xi; Qin Ning
Journal:  Hepatol Int       Date:  2017-01-17       Impact factor: 6.047

Review 2.  γδ T cells in liver diseases.

Authors:  Xuefu Wang; Zhigang Tian
Journal:  Front Med       Date:  2018-02-14       Impact factor: 4.592

3.  A new effect of IL-4 on human γδ T cells: promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells.

Authors:  Yujia Mao; Shanshan Yin; Jianmin Zhang; Yu Hu; Bo Huang; Lianxian Cui; Ning Kang; Wei He
Journal:  Cell Mol Immunol       Date:  2015-03-16       Impact factor: 11.530

Review 4.  Harnessing the power of Vδ2 cells in cancer immunotherapy.

Authors:  D W Fowler; M D Bodman-Smith
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

5.  CD137 Costimulation Enhances the Antitumor Activity of Vγ9Vδ2-T Cells in IL-10-Mediated Immunosuppressive Tumor Microenvironment.

Authors:  Yujun Pei; Zheng Xiang; Kun Wen; Chloe Ran Tu; Xiwei Wang; Yanmei Zhang; Xiaofeng Mu; Yinping Liu; Wenwei Tu
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

Review 6.  Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.

Authors:  Yue Chen; Haoyue Hu; Xianglei Yuan; Xue Fan; Chengda Zhang
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 7.  γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer.

Authors:  Bruno Silva-Santos; Sofia Mensurado; Seth B Coffelt
Journal:  Nat Rev Cancer       Date:  2019-07       Impact factor: 60.716

Review 8.  Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.

Authors:  Benjamin Ruf; Bernd Heinrich; Tim F Greten
Journal:  Cell Mol Immunol       Date:  2020-11-24       Impact factor: 11.530

9.  Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy.

Authors:  H Ryan Kolb; Nicholas Borcherding; Weizhou Zhang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

Review 10.  Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer.

Authors:  Yongyan Chen; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2020-10-12       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.